FDA Nod to Sarepta's (SRPT) DMD Gene Therapy Fuels Growth The Zacks Analyst is encouraged by the FDA approval to Sarepta's Elevidys, the first gene therapy for DMD. Based on this approval, it has started exploring opportunities in the gene therapy space.